Streetbeat News

Stock Prices

DUK

Duke Energy Inc.'s (NYSE:DUK) stock price is currently at $89.53, after a 2.33% increase. However, over the past month, the stock has decreased by 3.64%, and over the past year, it has decreased by 18.52%. The company's P/E ratio is lower than the aggregate P/E of the Electric Utilities industry, which could indicate that the stock is undervalued. However, a lower P/E can also suggest that shareholders do not expect future growth.

Portfolio Pulse from Benzinga Insights

September 07, 2023 | 6:15 pm

NRIX

SGEN

Nurix Therapeutics Inc (NRIX) and Seagen Inc (SGEN) have entered into a multi-year, multi-target strategic collaboration to develop a new class of cancer medicines called Degrader-Antibody Conjugates (DACs). Nurix will receive an upfront payment of $60 million and can receive up to approximately $3.4 billion in research, development, regulatory, and commercial milestone payments. Nurix's shares are up 9.77% following the announcement.

Portfolio Pulse from Vandana Singh

September 07, 2023 | 6:12 pm

UBER

Uber's CEO announced at the Goldman Sachs Conference that the company's delivery business is expected to grow by at least 14% in the second half of the year.

Portfolio Pulse from Benzinga Newsdesk

September 07, 2023 | 6:09 pm

ALNY

IONS

RHHBY

Alnylam Pharmaceuticals' KARDIA-1 Phase 2 study of zilebesiran, a drug for hypertension, has met its primary endpoint. The drug is being co-developed with Roche Holdings. The study showed a significant reduction in blood pressure and met key secondary endpoints. The results reaffirm the program's potential and could impact Ionis Pharmaceuticals, which is developing a similar therapeutic. Alnylam's shares are up 0.92%.

Portfolio Pulse from Vandana Singh

September 07, 2023 | 6:07 pm

RIVN

Rivian Automotive Inc's CFO announced at the Goldman Sachs Conference that the company has experienced significant deflation in battery material prices, which will continue to benefit the company.

Portfolio Pulse from Benzinga Newsdesk

September 07, 2023 | 6:03 pm

KURA

Analysts have provided bullish and somewhat bullish ratings for Kura Oncology (NASDAQ:KURA) in the last quarter. The average price target for KURA is $26.31, indicating a potential upside from its current price of $9.77. The average price target has increased by 9.62% over the past month.

Portfolio Pulse from Benzinga Insights

September 07, 2023 | 6:00 pm

VRT

Over the last quarter, Vertiv Hldgs (NYSE:VRT) has received 10 analyst ratings, with 8 being bullish or somewhat bullish, and 2 indifferent. The company's average 12-month price target has increased by 34.62% from $26.00 to $35.00, with a high of $50.00 and a low of $20.00.

Portfolio Pulse from Benzinga Insights

September 07, 2023 | 6:00 pm

PRTG

In the last quarter, Portage Biotech (NASDAQ:PRTG) received 4 bullish analyst ratings, with an average 12-month price target of $10.5, a decrease of 43.24% from the previous average price target of $18.50.

Portfolio Pulse from Benzinga Insights

September 07, 2023 | 6:00 pm

ARVN

Over the past 3 months, 8 analysts have published their opinion on Arvinas (NASDAQ:ARVN) stock. The average price target is $69.75, implying an upside from the current price of $26.3. This average has increased by 14.97% from the previous average price target of $60.67.

Portfolio Pulse from Benzinga Insights

September 07, 2023 | 6:00 pm

PII

Over the past 3 months, 8 analysts have published their opinion on Polaris (NYSE:PII) stock. The average price target is $133.0, implying an upside from the current price of $107.59. The current average has increased by 13.12% from the previous average price target of $117.57.

Portfolio Pulse from Benzinga Insights

September 07, 2023 | 6:00 pm